These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia. Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934 [TBL] [Abstract][Full Text] [Related]
4. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Li Q; Haigis KM; McDaniel A; Harding-Theobald E; Kogan SC; Akagi K; Wong JC; Braun BS; Wolff L; Jacks T; Shannon K Blood; 2011 Feb; 117(6):2022-32. PubMed ID: 21163920 [TBL] [Abstract][Full Text] [Related]
5. Cooperation of Dnmt3a R878H with Nras G12D promotes leukemogenesis in knock-in mice: a pilot study. Shi X; Yang Y; Shang S; Wu S; Zhang W; Peng L; Huang T; Zhang R; Ren R; Mi J; Wang Y BMC Cancer; 2019 Nov; 19(1):1072. PubMed ID: 31703632 [TBL] [Abstract][Full Text] [Related]
7. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Xu J; Haigis KM; Firestone AJ; McNerney ME; Li Q; Davis E; Chen SC; Nakitandwe J; Downing J; Jacks T; Le Beau MM; Shannon K Cancer Discov; 2013 Sep; 3(9):993-1001. PubMed ID: 23733505 [TBL] [Abstract][Full Text] [Related]
8. p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia. Zhang J; Kong G; Rajagopalan A; Lu L; Song J; Hussaini M; Zhang X; Ranheim EA; Liu Y; Wang J; Gao X; Chang YI; Johnson KD; Zhou Y; Yang D; Bhatnagar B; Lucas DM; Bresnick EH; Zhong X; Padron E; Zhang J Blood; 2017 Jan; 129(3):358-370. PubMed ID: 27815262 [TBL] [Abstract][Full Text] [Related]
9. RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia. Kim WI; Matise I; Diers MD; Largaespada DA Blood; 2009 Jan; 113(5):1086-96. PubMed ID: 18952898 [TBL] [Abstract][Full Text] [Related]
11. BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3. Nordigården A; Kraft M; Eliasson P; Labi V; Lam EW; Villunger A; Jönsson JI Blood; 2009 Mar; 113(10):2302-11. PubMed ID: 19064725 [TBL] [Abstract][Full Text] [Related]
12. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Borthakur G; Popplewell L; Boyiadzis M; Foran J; Platzbecker U; Vey N; Walter RB; Olin R; Raza A; Giagounidis A; Al-Kali A; Jabbour E; Kadia T; Garcia-Manero G; Bauman JW; Wu Y; Liu Y; Schramek D; Cox DS; Wissel P; Kantarjian H Cancer; 2016 Jun; 122(12):1871-9. PubMed ID: 26990290 [TBL] [Abstract][Full Text] [Related]
13. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation. You X; Liu F; Binder M; Vedder A; Lasho T; Wen Z; Gao X; Flietner E; Rajagopalan A; Zhou Y; Finke C; Mangaonkar A; Liao R; Kong G; Ranheim EA; Droin N; Hunter AM; Nikolaev S; Balasis M; Abdel-Wahab O; Levine RL; Will B; Nadiminti KVG; Yang D; Geissler K; Solary E; Xu W; Padron E; Patnaik MM; Zhang J Blood; 2022 Feb; 139(7):1066-1079. PubMed ID: 34699595 [TBL] [Abstract][Full Text] [Related]
14. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Posch C; Moslehi H; Feeney L; Green GA; Ebaee A; Feichtenschlager V; Chong K; Peng L; Dimon MT; Phillips T; Daud AI; McCalmont TH; LeBoit PE; Ortiz-Urda S Proc Natl Acad Sci U S A; 2013 Mar; 110(10):4015-20. PubMed ID: 23431193 [TBL] [Abstract][Full Text] [Related]
15. Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions. Wang J; Kong G; Liu Y; Du J; Chang YI; Tey SR; Zhang X; Ranheim EA; Saba-El-Leil MK; Meloche S; Damnernsawad A; Zhang J; Zhang J Blood; 2013 Jun; 121(26):5203-7. PubMed ID: 23687087 [TBL] [Abstract][Full Text] [Related]
16. Oncogenic N-Ras and Tet2 haploinsufficiency collaborate to dysregulate hematopoietic stem and progenitor cells. Jin X; Qin T; Zhao M; Bailey N; Liu L; Yang K; Ng V; Higashimoto T; Coolon R; Ney G; Figueroa ME; Li Q Blood Adv; 2018 Jun; 2(11):1259-1271. PubMed ID: 29866713 [TBL] [Abstract][Full Text] [Related]
18. Nras Q61R/+ and Kras-/- cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors. Wen Z; Yun G; Hebert A; Kong G; Ranheim EA; Finn R; Rajagoplan A; Li S; Zhou Y; Yu M; Damnernsawad A; Roose JP; Coon JJ; Wen R; Wang D; Zhang J Blood; 2021 Jun; 137(23):3259-3271. PubMed ID: 33512434 [TBL] [Abstract][Full Text] [Related]
19. First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia. Cho H; Shin I; Ju E; Choi S; Hur W; Kim H; Hong E; Kim ND; Choi HG; Gray NS; Sim T J Med Chem; 2018 Sep; 61(18):8353-8373. PubMed ID: 30153003 [TBL] [Abstract][Full Text] [Related]
20. C57BL/6 congenic mouse NRAS Petit V; Raymond J; Alberti C; Pouteaux M; Gallagher SJ; Nguyen MQ; Aplin AE; Delmas V; Larue L Pigment Cell Melanoma Res; 2019 Nov; 32(6):829-841. PubMed ID: 31251472 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]